Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$153.49 USD

153.49
4,164,591

+3.73 (2.49%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Neogen Gains on Strong Genomic Arm Amid Stiff Competition

Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.

Illumina (ILMN) Is Up 1.45% in One Week: What You Should Know

Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is Why Growth Investors Should Buy Illumina (ILMN) Now

Illumina (ILMN) could produce exceptional returns because of its solid growth attributes.

Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?

Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.

Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.

Henry Schein Animal Health Spin-Off Approaches, Cost Mounts

Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.

Illumina (ILMN) Gains But Lags Market: What You Should Know

Illumina (ILMN) closed at $305.63 in the latest trading session, marking a +0.05% move from the prior day.

The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana

The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana

Why You Should Consider Buying Omnicell (OMCL) Stock Now

Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.

Swarup Gupta headshot

5 Great Medical Stocks to Buy Ahead of Q4 Earnings

A Reuters review of Wall Street Research firms reveals that health care is the most favored of the S&P 500's 11 major sectors.

QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands

QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.

Here's Why You Should Invest in Illumina (ILMN) Stock Now

Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.

Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

Is (ILMN) Outperforming Other Medical Stocks This Year?

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know

Illumina (ILMN) closed the most recent trading day at $307.89, moving +1.72% from the previous trading session.

Urmimala Biswas headshot

3 Medical Stocks Likely to Emulate Illumina's Success in 2019

Illumina's (ILMN) gains are indeed staggering. But is it the sole star in the firmament setting benchmarks for others to try and emulate?

Here's Why You Should Buy Express Scripts (ESRX) Stock Now

Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.

AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals

AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.

Here's Why You Should Hold Allscripts Stock in Your Portfolio

Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.

Nitish Marwah headshot

New Strong Buy Stocks for December 14th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

Is (ILMN) Outperforming Other Medical Stocks This Year?

BD Gets Enterprise Level Cybersecurity Assessment From UL

BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.

Here's Why Investors Should Hold Masimo (MASI) Stock Now

Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.

Illumina (ILMN) Takes Part in NIH Program With Genotype Launch

The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.